RPAP2

Across TCGA pan-cancer cohorts, RPAP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPAP2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPAP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPAP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where RPAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.781	0.431	<.001	66	view →
CCRCC	DFS	Quartile	All	0.215	0.844	.008	27	view →
LSCC	DFS	Median	II,III,IV	1.000	0.862	.004	10	view →
GBM	OS	Median	All	0.418	0.654	.005	9	view →
PDAC	OS	Tertile	III,IV	0.814	0.311	.024	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPAP2–LUAD (DFS)

Open the LUAD breakdown →